Literature DB >> 25717264

Autoimmune hepatitis-primary biliary cirrhosis concurrent with biliary stricture after liver transplantation.

Yong-Zhen Kang1, Xiao-Ye Sun1, Yi-He Liu1, Zhong-Yang Shen1.   

Abstract

Although the development of de novo autoimmune liver disease after liver transplantation (LT) has been described in both children and adults, autoimmune hepatitis (AIH)-primary biliary cirrhosis (PBC) overlap syndrome has rarely been seen in liver transplant recipients. Here, we report a 50-year-old man who underwent LT for decompensated liver disease secondary to alcoholic steatohepatitis. His liver function tests became markedly abnormal 8 years after LT. Standard autoimmune serological tests were positive for anti-nuclear and anti-mitochondrial antibodies, and a marked biochemical response was observed to a regimen consisting of prednisone and ursodeoxycholic acid added to maintain immunosuppressant tacrolimus. Liver biopsy showed moderate bile duct lesions and periportal lymphocytes infiltrating along with light fibrosis, which confirmed the diagnosis of AIH-PBC overlap syndrome. We believe that this may be a case of post-LT de novo AIH-PBC overlap syndrome; a novel type of autoimmune overlap syndrome.

Entities:  

Keywords:  Autoimmune hepatitis; Autoimmune liver disease; Biliary stricture; Liver transplantation; Overlap syndrome; Primary biliary cirrhosis

Mesh:

Substances:

Year:  2015        PMID: 25717264      PMCID: PMC4326166          DOI: 10.3748/wjg.v21.i7.2236

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  22 in total

Review 1.  Autoimmune overlap syndromes.

Authors:  J Woodward; J Neuberger
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

2.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

3.  EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

Authors: 
Journal:  J Hepatol       Date:  2009-06-06       Impact factor: 25.083

4.  Primary biliary cirrhosis.

Authors:  Keith D Lindor; M Eric Gershwin; Raoul Poupon; Marshall Kaplan; Nora V Bergasa; E Jenny Heathcote
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

5.  Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.

Authors:  Ersan Ozaslan; Cumali Efe; Alexandra Heurgué-Berlot; Taylan Kav; Chiara Masi; Tugrul Purnak; Luigi Muratori; Yücel Ustündag; Solange Bresson-Hadni; Gérard Thiéfin; Thomas D Schiano; Staffan Wahlin; Paolo Muratori
Journal:  Clin Gastroenterol Hepatol       Date:  2013-09-26       Impact factor: 11.382

6.  Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid.

Authors:  Christoph Loddenkemper; Sylvia Keller; Marie-Loise Hanski; Minh Cao; Gerhard Jahreis; Harald Stein; Martin Zeitz; Christoph Hanski
Journal:  Int J Cancer       Date:  2006-06-01       Impact factor: 7.396

Review 7.  Overlap syndromes among autoimmune liver diseases.

Authors:  Christian Rust; Ulrich Beuers
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 8.  Update on autoimmune hepatitis.

Authors:  Andreas Teufel; Peter R Galle; Stephan Kanzler
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

9.  Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival.

Authors:  T Al-Chalabi; B C Portmann; W Bernal; I G McFarlane; M A Heneghan
Journal:  Aliment Pharmacol Ther       Date:  2008-04-23       Impact factor: 8.171

10.  Autoimmune liver disease - are there spectra that we do not know?

Authors:  Hind I Fallatah; Hisham O Akbar
Journal:  Comp Hepatol       Date:  2011-09-12
View more
  2 in total

1.  18β-Glycyrrhetinic acid protects against alpha-naphthylisothiocyanate-induced cholestasis through activation of the Sirt1/FXR signaling pathway.

Authors:  Shou-Yan Wu; Shi-Chao Cui; Le Wang; Yi-Ting Zhang; Xiao-Xia Yan; Heng-Lei Lu; Guo-Zhen Xing; Jin Ren; Li-Kun Gong
Journal:  Acta Pharmacol Sin       Date:  2018-07-30       Impact factor: 6.150

2.  Huangqi Decoction Alleviates Alpha-Naphthylisothiocyanate Induced Intrahepatic Cholestasis by Reversing Disordered Bile Acid and Glutathione Homeostasis in Mice.

Authors:  Jia-Sheng Wu; Yi-Fei Li; Yuan-Yuan Li; Yan Dai; Wen-Kai Li; Min Zheng; Zheng-Chun Shi; Rong Shi; Tian-Ming Wang; Bing-Liang Ma; Ping Liu; Yue-Ming Ma
Journal:  Front Pharmacol       Date:  2017-12-21       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.